Biosimilars Review
Impact of increasing Global Competition on Biosimilars

Over the past 30 years, biological therapeutics have significantly transformed treatment options and improved outcomes for millions of individuals who face a range of life-threatening diseases. Not only have biologics improved outcomes, but in many cases, they have fostered a better quality of life compared with earlier therapies.

As a brand name, innovator biological drugs go off patent, biosimilars represent an opportunity to develop lower-cost options. US Food and Drug Administration (FDA) commissioner Scott Gottleib, MD, says, “Effective biosimilar products are key for patients and our nation’s health care system.”

Download this report, which dives into the impact of increasing global competition on Biosimilars.



Sponsored By:

Download the report:
This site is owned and operated by Informa plc ("informa") whose registered office is 5 Howick place, London SW1P 1WG. Registered in England and Wales Number 1072954.
Privacy Policy | Terms